# Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

> **NCT03890055** · PHASE4 · UNKNOWN · sponsor: **Chifeng Municipal Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT03890055
- **Lead sponsor:** Chifeng Municipal Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03890055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03890055, "Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03890055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*